Inactive Instrument

Amryt Pharma plc Stock price London S.E.

Equities

GB00BKB1MS30_GB

GB00BKLTQ412

Pharmaceuticals

Dynamic Chart
Managers TitleAgeSince
Founder 53 19-09-23
Director of Finance/CFO 56 19-09-12
Chief Tech/Sci/R&D Officer - 20-03-31
Members of the board TitleAgeSince
Director/Board Member 67 19-09-23
Chairman 77 15-12-31
Founder 53 19-09-23
More insiders
Amryt Pharma plc is a commercial-stage biopharmaceutical company. It is focused on acquiring, developing, and commercializing novel treatments for rare diseases. Its commercial business comprises three orphan disease products, such as metreleptin (Myalept/ Myalepta); lomitapide (Juxtapid/ Lojuxta), and oral octreotide (Mycapssa). Myalept is approved in the United States as an adjunct to diet as replacement therapy to treat leptin deficiency in patients with congenital or acquired generalised lipodystrophy (GL). Juxtapid is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, homozygous familial hypercholesterolaemia (HoFH). Mycapssa is a combination of octreotide acetate and excipients, collectively called Transient Permeability Enhancer (TPE). Its development candidate, Oleogel-S10 (Filsuvez) is a treatment for the cutaneous manifestations of junctional and dystrophic (JEB and DEB) epidermolysis bullosa.
More about the company
  1. Stock
  2. Equities
  3. Stock Amryt Pharma plc
  4. Stock Amryt Pharma plc - London S.E.